Stock Price & Analysis

Based on the provided data and recent market developments, here's a concise analysis of CI stock:

Recent Price Action and Technical Analysis

The stock has shown a strong upward momentum since January 2024, rising from around $296 to current levels near $300. The stock is currently trading above both its 50-day and 200-day moving averages, indicating positive technical momentum.

Key Recent Events

1. Medicare Business Sale: On January 31, 2024, Cigna announced the sale of its Medicare businesses and CareAllies to Health Care Service Corporation (HCSC) for $3.7 billion. The transaction is expected to:

• Close in Q1 2025
• Be accretive to adjusted EPS in 2025
• Majority of proceeds will be used for share repurchases

2. Regulatory Environment: The health insurance sector is experiencing significant shifts with:

• Government proposing increased Medicare Advantage plan payments for 2026
• Estimated 4.3% total payment increase, or over $21 billion
• Favorable proposal given the current political environment

Analyst Sentiment

Recent analyst views indicate:

• Jefferies maintains a Buy rating
• Expectations of relatively benign pharmacy benefit management regulations
• Projected 14% EPS growth for 2026
• Price target range of $323-$438, suggesting significant upside potential

Recommendation

Based on the technical analysis, recent strategic moves, and analyst sentiment, CI stock appears to be a BUY at current levels. The company's strategic divestment of Medicare businesses, focus on core operations, and strong analyst support suggest potential upside in the near term.

Based on the provided data and market analysis, here is the price prediction for CI (Cigna) stock in 2025:

Technical Analysis

The current technical indicators show:

• RSI at 56.16 indicates neutral momentum
• MACD is positive at 1.94 with rising histogram (0.78)
• Stock is trading above key SMAs (5,10,20-day) but below 200-day SMA
• Bollinger Band position (0.65) suggests moderate upward momentum

Fundamental Drivers & Price Targets

According to analyst forecasts and company guidance:

• Consensus price target is $374.29 by end of 2025, representing ~25% upside from current levels
• Management projects at least 10% profit growth in 2025
• Key growth drivers include:
  • Strong biosimilar adoption trends
  • Specialty pharmacy expansion
  • Strategic investments in customer initiatives
  • Share buybacks from Medicare business sale proceeds

2025 Price Prediction

Based on technical and fundamental analysis, CI stock is expected to trade in the following ranges in 2025:

• Base case: $340-370 (most likely)
• Bull case: $380-400
• Bear case: $300-320

The stock is likely to reach $365-370 by end of 2025 driven by:

1. Continued execution in core business segments
2. Benefits from strategic investments
3. Ongoing capital return to shareholders

The S1 support level for CI Stock is $290.58 ,The R1 resistant level for CI Stock is $310.95.

As of the end of day on 2025-02-26, the price of CI Stock was $313.01.

The target price for CI Stock according to analyst rating is 365.39, with the highest price target at 420.00 and the lowest at 323.00. Analysts have a Strong Buy rating on CI Stock overall.

The market cap of CI is $85.9B.

Based on the provided data and recent analyst reports, here's a concise analysis of CI's valuation:

Technical Analysis

CI is currently trading at $302, showing signs of consolidation with RSI at 56.16 indicating neutral momentum. The stock is below both its 200-day ($324.11) and 250-day ($328.48) moving averages, suggesting bearish long-term trend.

Valuation Metrics

• Forward P/E: 17.22x (increased from 15.47x in 2022)
• EV/EBITDA: 9x (improved from 10.67x in 2022)
• P/S: 0.46x (decreased from 0.57x in 2022)
• P/B: 1.89x (decreased from 2.22x in 2022)

Recent Developments The company received positive news regarding Medicare Advantage payments, with proposed 2026 rates suggesting a 4.3% increase. Multiple analysts maintain Buy ratings with price targets ranging from $339-$391, citing:

• Conservative 2025 guidance suggesting upside potential
• Strong yield and organic growth expectations
• Strategic positioning in commercial markets

Conclusion CI appears fairly valued at current levels considering its improved EV/EBITDA multiple and growth prospects. The stock is trading below historical averages but has strong analyst support and positive regulatory tailwinds. The current technical setup suggests potential for mean reversion toward the 200-day moving average.

The Cigna Group is a global health services company. Its portfolio of offerings solves diverse challenges across the healthcare system. It offers a differentiated set of pharmacy, medical, behavioral, dental, and supplemental products, and services, primarily through two platforms: Evernorth Health Services and Cigna Healthcare. Evernorth Health Services includes a range of coordinated and point solution health services and capabilities, as well as those from partners across the health care system, in pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions, which are provided to health plans, employers, government organizations and health care providers. Evernorth Health Services also offers MDLIVE virtual care platform. Cigna Healthcare includes the United States Commercial, United States Government, and International Health operating segments, which provide medical and coordinated solutions to clients and customers.

Based on the provided data and market research, here is a price prediction analysis for Cigna (CI) stock by 2030:

Price Target 2030: $450-500

The projection is supported by several key factors:

1. Growth Drivers:

• Strong performance in Evernorth segment with specialty pharmacy volume growth
• Strategic investments in customer and provider-facing initiatives
• Continued focus on operational efficiency and margin improvements

2. Market Position:

• Leading position in health services and insurance sectors
• Strong client retention rates and growing market share
• Expanding digital health capabilities and value-based care initiatives

Current Market Context:

• Trading at $302 (as of Feb 24, 2025)
• Technical indicators show potential for upward momentum with RSI at 56.16
• Support levels around $287 and resistance near $306 based on Fibonacci levels

Key Catalysts Supporting the Target:

• Healthcare sector transformation and aging population demographics
• Expansion of specialty pharmacy and care delivery services
• Strategic M&A opportunities in digital health space

The price target of $450-500 by 2030 represents approximately 50-65% upside from current levels, implying a compound annual growth rate (CAGR) of 8-10% over the next 5 years.

CI has a total of 72500 employees.